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Objectives We sought to determine the effect of baroreflex activation therapy (BAT) on systolic blood pressure (SBP) in
patients with resistant hypertension.
Background The Rheos Pivotal Trial evaluated BAT for resistant hypertension in a double-blind, randomized, prospective,
multicenter, placebo-controlled Phase III clinical trial.
Methods This was a double-blind randomized trial of 265 subjects with resistant hypertension implanted and subse-
quently randomized (2:1) 1 month after implantation. Subjects received either BAT (Group A) for the first
6 months or delayed BAT initiation following the 6-month visit (Group B). The 5 coprimary endpoints were:
1) acute SBP responder rate at 6 months; 2) sustained responder rate at 12 months; 3) procedure safety;
4) BAT safety; and 5) device safety.
Results The trial showed significant benefit for the endpoints of sustained efficacy, BAT safety, and device safety. How-
ever, it did not meet the endpoints for acute responders or procedural safety. A protocol-specified ancillary anal-
ysis showed 42% (Group A) versus 24% (Group B) achieving SBP 140 mm Hg at 6 months (p  0.005), with
both groups achieving over 50% at 12 months, at which point Group B had received 6 months of BAT.
Conclusions A clinically meaningful measure, those achieving a SBP of 140 mm Hg, yielded a significant difference be-
tween the groups. The weight of the overall evidence suggests that over the long-term, BAT can safely reduce
SBP in patients with resistant hypertension. Future clinical trials will address the limitations of this study and
further define the therapeutic benefit of BAT. (J Am Coll Cardiol 2011;58:765–73) © 2011 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.06.008Resistant hypertension (HTN) is defined as failure to
achieve goal blood pressure (BP) (140/90 mm Hg for
most patients, 130/80 mm Hg for patients with diabetes
or chronic kidney disease) when adhering to maximally
tolerated doses of 3 appropriate antihypertensive drugs
including a diuretic. Resistant HTN is frequently associated
with comorbidities such as obesity, diabetes, and chronic
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studies indicate 20% to 30% of hypertensive patients have
treatment-resistant HTN (1–3). Even with application of
existing pharmacotherapies, the prevalence of resistant
HTN is expected to increase in coming decades due to the
aging of the population together with an increased burden
of cardiovascular disease and obesity/metabolic syndrome
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HTN contributes to end-organ
damage and mortality. The med-
ical and social burdens of inade-
quately treated HTN have stim-
ulated investigation of additional
therapeutic options in patients
with resistant HTN.
Compensatory changes in sym-
pathetic nervous system function
are an important component of
heart failure and primary HTN.
Decreased parasympathetic and increased sympathetic tone
increase peripheral vascular resistance, reduce renal blood
flow, and increase sodium retention, while impairing glu-
cose handling and contributing to adverse cardiac and
vascular remodeling (4). A new surgically implantable de-
vice for the treatment of resistant HTN (Rheos System,
CVRx, Inc., Minneapolis, Minnesota) has been developed
to administer baroreflex activation therapy (BAT) via elec-
trical stimulation of the carotid baroreceptors. BAT mod-
ulates sympathovagal balance that is commonly deranged in
patients with HTN as evidenced by recent findings that
show BAT acutely reduced muscle sympathetic nerve activ-
ity (5) and increased parasympathetic activity (6). The
current article presents results from the Rheos Pivotal Trial,
a randomized, double-blind, placebo-controlled study in
patients with resistant HTN.
Methods
Study design. The Rheos Pivotal Trial (NCT00442286)
was a randomized, double-blind, parallel-design clinical
trial designed to assess the efficacy and safety of the Rheos
System in patients with resistant HTN as shown in Figure 1.
The trial was approved by the Food and Drug Adminis-
tration under an investigational device exemption. The
institutional review board or ethics committee at each
participating institution approved the protocol prior to
the start of the trial, and all subjects provided written
informed consent prior to any protocol-required proce-
dures being conducted.
Abbreviations
and Acronyms
BAT  baroreflex activation
therapy
BP  blood pressure
DMC  data monitoring
committee
HTN  hypertension
SBP  systolic blood
pressure
Figure 1 Trial Schematic Showing the Visit Intervals During the
Subjects were randomized 2:1 to Group A (device on) versus Group B (device off)Patient population. The main enrollment criterion was
resistant HTN defined as at least 1 out-patient, in-office,
systolic blood pressure (SBP) 160 mm Hg with diastolic
BP 80 mm Hg taken per protocol utilizing a standardized
device described later in the text. This measurement was
obtained following at least 1 month of maximally tolerated
therapy with at least 3 appropriate antihypertensive medica-
tions, including a diuretic. An ambulatory SBP135 mm Hg
or a 24-h average, obtained via a standardized protocol and
ssessed at a core laboratory, and an absence of clinically
ignificant orthostatic BP changes were additional enroll-
ent criteria. Forty-nine centers consented 590 subjects for
creening between March 2007 and November 2009. The
tatus of all subjects who consented to participate in the trial
s shown in Figure 2. To account for an anticipated learning
urve with the Rheos System implantation procedure, each
nrollment center was allowed to implant up to 2 nonran-
omized (open-label) subjects prior to enrolling subjects in
he randomized portion of the trial. The main reasons for
neligibility were due to office SBP or 24-h ambulatory SBP
elow inclusion criteria, the presence of carotid stenosis, or
he subject being an inappropriate surgical candidate as
ssessed by the vascular surgeon investigator. Of the 326
ubjects eligible for implantation, 4 did not exhibit an acute
esting response during surgery and, ultimately, were not
mplanted with the device. Two additional implanted sub-
ects that should have been randomized had the device
xplanted prior to the randomization visit due to infection
nd thus were never randomized. A total of 265 subjects
ere randomized 2:1, 181 to Group A (immediate BAT)
nd 84 to Group B (BAT deferred until after Month 6).
hree subjects (2 in Group A, 1 in Group B) met the
mergency unblinding criteria of hypertensive emergency
ith confirmed diastolic BP of 120 mm Hg or greater with
vidence of accelerated symptoms of end-organ damage and
ad their treatment assignment revealed prior to the
-month visit.
rocedures. All eligible subjects were implanted with the
heos System (CVRx) by a vascular, cardiothoracic, or
eurosurgeon as previously described (7). The device con-
isted of a pulse generator and leads that were separately
onth Blinded Follow-Up Period
the first 6-month period.12-M
during
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Figure 3 provides an illustration of the implant site of the
electrode and device. Once the device was activated 1 month
post-implant, stimulation parameters were adjusted accord-
ing to a protocol-defined algorithm to provide a gradual
increase in baroreflex activation such that optimal therapy,
including the option of bilateral or unilateral stimulation,
was being provided by the fifth month after device activa-
tion. BAT was individually titrated within a protocol-
defined set of parameters, and best practices were shared
across centers. Subjects and investigators remained blinded
to treatment until after the 12-month visit.
Field clinical engineers from the sponsor worked under
Figure 2 Trial Subject Status Profile
All subjects that gave signed consent are summarized with status through
Month 12. A total of 265 subjects were randomized and are included in the
intention-to-treat analyses. Three subjects (2 in Group A, 1 in Group B) were
unblinded during the initial 6 months of the trial.the supervision of principal investigators and research coor-dinators to ensure that the device was programmed opti-
mally for all patients in the study. These processes were
done after best-practice methods had been determined from
earlier clinical trials. All of this was done in an effort to
minimize any intercenter differences in programming.
Out-patient office BP was assessed using a standardized,
automated device (BpTRU, VSM Medtech Ltd., Vancou-
ver, Canada) that was programmed to take 6 measurements
at 1-min intervals and report the average of the last 5 of
these measurements, which were taken with the investigator
not in the room. In clinical testing, this method minimizes
the “white coat” effect, and the results of these measure-
ments compare well to daytime ambulatory BP (8). Blood
pressure assessments were taken at a consistent time of day
and within 4 to 6 h of the most recent dose of antihyper-
tensive medication(s). As part of ongoing subject medical
management, investigators were not prevented from chang-
ing antihypertensive medications during the course of the
trial.
All adverse events were reviewed and submitted for
adjudication to an independent adverse events committee.
Serious adverse events included death, life-threatening
events, hospitalization or prolongation of a hospitalization,
permanent functional or structural damage, or other medical
events.
Endpoints. The Rheos Pivotal Trial was designed to dem-
onstrate the efficacy and safety of the Rheos device via 5
pre-specified coprimary endpoints, 2 for efficacy and 3 for
safety, as follows: 1) acute efficacy; 2) sustained efficacy;
3) procedural safety; 4) BAT safety; and 5) device safety.
The trial also had prespecified secondary endpoints for
mean change in office SBP and a comparison of immediate
versus deferred (delayed) BAT. The details of the primary
and secondary endpoint analyses are given in the Statistical
Analysis section that follows.
Statistical analysis. Per trial design assumptions, sample
size was calculated to adequately power all coprimary
endpoints. The sustained efficacy response endpoint re-
Figure 3 Illustration of the Implantation of the Rheos System
The device consists of bilateral electrodes and a pulse generator.
Programming is accomplished via an external programming system.
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responders at Month 6 in Group A, yielding a needed
sample size of 148 in Group A to attain 90% power to detect
a sustained response at Month 12 of 80% with a 15%
noninferiority margin. With this total sample size (148 in
Group A and 74 in Group B to accommodate the 2:1
randomization), all other primary and secondary endpoints
had at least 90% power. Prespecified analyses were per-
formed according to a pre-established statistical analysis
plan. Interim statistical analyses were performed at 6-month
intervals for the data monitoring committee, which re-
viewed the results blinded to treatment group. After all
subjects had been enrolled and implanted, and at a point
when 95 subjects had not yet completed the 6-month visit,
the DMC advised the sponsor that the trial was unlikely to
attain significance for the acute efficacy analysis. The DMC
recommended that all subjects be allowed to complete the
6-month visit in a blinded fashion.
Comparisons among randomized groups of clinical base-
line and demographic data were performed with t tests for
ontinuous variables and chi-square tests for categorical
ariables. Comparisons within patients were made with
aired-sample t tests. Statistical analysis was performed
arametrically and 2-sided using SAS version 9.2 statistical
oftware (SAS Institute, Cary, North Carolina). An alpha
evel of 0.05 was used to denote statistical significance. Data
re presented as mean  SD of the mean unless otherwise
noted.
Primary endpoints. The components of the primary end-
point included acute and sustained efficacy as well as
procedural, BAT, and device safety. Since all coprimary
endpoints had to be met in order to demonstrate overall
efficacy and safety, no adjustment to the significance level
was required to account for multiple tests of hypotheses.
Efficacy analyses were conducted according to the principles
of intention to treat, with unblinded and withdrawn subjects
treated as failures. Only BP assessments made utilizing the
BpTRU device per protocol and within the protocol-
specified visit window were used. Change in BP was
calculated using the average of the 5 measurements from the
BpTRU device at each visit and Month 0 defined as the BP
obtained at the randomization visit 1-month post-implant.
Safety analyses were conducted using the assessment of the
independent adverse events committee. All subjects in the
randomized portion of the trial were included in the safety
evaluation. For all safety evaluations, subjects were censored
at the date of last known endpoint status.
ACUTE EFFICACY. Compare Group A versus Group B via a
ouble-blind, randomized, parallel-group, super-superiority
esign for proportion of subjects that achieve at least a 10
m Hg drop in SBP at Month 6 compared with Month 0,
ith a superiority margin of 20%.
SUSTAINED EFFICACY. Compare the sustained response in
SBP Month 12 in Group A responders at Month 6 to an
objective performance criterion of 65%. A sustained re- asponse to therapy required the reduction from Month 0 to
Month 12 to be at least 10 mm Hg and to remain at least
50% of that seen at Month 6. For example, if a responder
had a drop of 50 mm Hg from Month 0 to Month 6, then
the reduction from Month 0 to Month 12 would have to be
at least 25 mm Hg to qualify as a sustained response.
PROCEDURAL SAFETY. Compare the serious procedure- or
ystem-related adverse event–free rate for events occurring
ithin 30 days of implant to a pre-specified objective
erformance criterion of 82% based on historical literature
n implantable cardioverter-defibrillators and pacemakers.
BAT SAFETY. Compare Group A versus Group B therapy-
elated adverse event–free rates via a double-blind, random-
zed, parallel-group, noninferiority design for therapy-
elated serious adverse events occurring between 30 days
ost-implant and the Month 6 visit. The noninferiority
argin was 15%. Therapy-related adverse events included
vents attributable to therapy to treat resistant hypertension,
ncluding but not limited to serious adverse drug reactions,
ypotension, bradycardia, hypertensive crisis requiring hos-
italization, and extraneous stimulation.
DEVICE SAFETY. Compare the event-free rate for all major
ypertension-related and serious device-related adverse
vents occurring between 30 days post-implant and the
onth 12 visit, to a pre-specified objective performance
riterion of 72% based on similar implantable devices such
s defibrillators and resynchronization devices. Hypertension-
elated adverse events include fatal and nonfatal myocardial
nfarction (at least 2 of 3 standard criteria: typical chest pain,
lectrocardiogram changes, elevation of myocardial enzymes
y more than 2-fold the upper normal limits), heart failure
equiring hospitalization (at least 2 major or 1 major plus 2
inor Framingham criteria), fatal and nonfatal stroke (rapid
nset of localized neurological deficit lasting 24 hours
ith computed tomography evidence), and renal failure
equiring dialysis.
econdary endpoints. MEAN CHANGE IN SBP. Compare
Group A versus Group B via a double-blind, randomized,
parallel-group, superiority design for mean change in SBP
at Month 6 compared with Month 0.
IMMEDIATE VERSUS DEFERRED BAT. Compare Group A
ersus Group B via a randomized, blinded, parallel-group,
oninferiority design for mean change in SBP at Month 12
ompared with Month 0. Group A will have had therapy for
2 months whereas Group B will have had therapy for 6
onths. The noninferiority margin was 7.5 mm Hg.
esults
atient cohort. The 2 randomized groups were well
atched for clinical baseline and demographic characteris-
ics as shown in Table 1. Antihypertensive medications
veraged 5.2 1.7. Over 90% of patients were on a diuretic,
nd 27% of subjects were on a drug regimen that included
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lytic agent at trial entry. The average follow-up was 21  8
months with a total of 463 person-years of follow-up. A
single subject, in Group A, was determined to be lost to
follow-up prior to the 12-month visit.
Primary efficacy endpoints. A summary of the results
from the 5 coprimary endpoints is presented in Table 2,
Baseline CharacteristicsTable 1 Baseline Characteristics
Group A Group B
(n  181) (n  84)
Sex
Male 116 (64%) 46 (55%)
Female 65 (36%) 38 (45%)
Age, yrs 53.7 10.5 52.4 9.8
Race
Caucasian 146 (81%) 59 (70%)
Black 30 (17%) 18 (21%)
BP, mm Hg
Systolic 169 26 168 24
Diastolic 101 17 100 14
Heart rate, beats/min 79 14 79 17
Body mass index, kg/m2 32.6 (5.4%) 32.2 (5.9%)
Diabetes 57 (31%) 29 (35%)
Previous CAD 38 (21%) 18 (21%)
Heart failure 12 (7%) 10 (12%)
Previous stroke 24 (14%) 9 (11%)
Number of BP medications 5.2 (1.6) 5.2 (1.8)
BP medications
3 23 (13%) 13 (16%)
4 40 (22%) 22 (26%)
5 118 (65%) 49 (58%)
ACE inhibitor 103 (57%) 45 (54%)
Angiotensin receptor blocker 85 (47%) 36 (43%)
Direct renin inhibitor 29 (16%) 13 (15%)
Beta-blocker 155 (86%) 70 (83%)
Calcium-channel blocker 117 (65%) 60 (71%)
Diuretic 174 (96%) 77 (92%)
Aldosterone antagonist 31 (17%) 16 (19%)
Direct vasodilators 58 (32%) 25 (30%)
Alpha-blocker 21 (12%) 15 (18%)
Centrally acting sympatholytic agents 79 (44%) 44 (52%)
Values are absolute n (%) or mean  SD. No significant differences were detected between the
2 groups.
ACE  angiotensin-converting enzyme; BP  blood pressure; CAD  coronary artery disease.
Summary of Coprimary EndpointsTable 2 Summary of Coprimary Endpoints
Endpoint Design
Timing Type
Efficacy endpoints
Acute responder 6 months Super-superiority A 
Sustained responder 12 months OPC 12
Safety endpoints
Procedure 30 days OPC 30
BAT 6 months Noninferiority A 
Device 12 months OPC 12BAT  baroreflex activation therapy; CB  confidence bound; OPC  objective performance criterion.and the details are discussed below in terms of efficacy
and safety.
ACUTE EFFICACY. The responder analysis at 6 months
yielded 54% responders in Group A and 46% responders in
Group B, which did not represent a significant difference
with the 20% superiority margin (p  0.97).
SUSTAINED EFFICACY. The sustained responder analysis
ielded 88% of responders at 6 months, maintaining that
esponse at 12 months per the protocol definition (p 
.001).
econdary endpoints. MEAN CHANGE IN SBP. Mean de-
crease in SBP at 6 months from Month 0 was 16  29 mm
Hg for Group A and 9  29 mm Hg for Group B (p 
0.08).
IMMEDIATE VERSUS DEFERRED BAT. Mean decrease in
BP at 12 months from Month 0, at which point Group A
ad received 12 months of BAT and Group B had received
months of BAT, was 25  32 mm Hg for Group A and
5  31 mm Hg for Group B.
dditional efficacy analyses. An ancillary analysis was
ercentage of subjects attaining SBP 140 mm Hg at 6
nd 12 months as shown in Figure 4. A significant
ifference is observed between the 2 groups at 6 months
p  0.005), and no difference is observed at 12 months
p  0.70) when both groups have received BAT for at
least 6 months.
A post hoc analysis utilizing change from pre-implant
rather than from Month 0 was performed due to the
unexpected differences between the pre-implant and
Month 0 SBP values and allows for more direct compar-
ison to drug therapies and other therapies. Changes at 6
and 12 months from pre-implant are shown in Figure 5
and yielded a decrease in SBP of 26  30 mm Hg for
Group A and 17  29 mm Hg for Group B (p  0.03) at
6 months and a decrease of 35  28 mm Hg for Group A
and 33 30 mm Hg for Group B (p 0.57) at 12 months.
t 12 months, the SBP of 81% of subjects had dropped at
east 10 mm Hg from pre-implant. This responder group
xperienced an average SBP drop of 44 mm Hg, and 63% of
hese subjects reached SBP of 140 mm Hg.
Endpoint Results
n Point Estimate Lower CB p Value
20% 265 7.7 5.1 0.97
65% 97 87.6 81.1 0.001
2% 265 74.8 70.5 1.00
15% 265 2.4 4.1 0.001
72% 265 87.2 83.8 0.001HA
B 
Month 
day 8
B 
Month 
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Baroreflex Activation Therapy in Hypertension August 9, 2011:765–73Adverse events. GENERAL. There were a total of 7 deaths
(4 occurring during the initial 12 months of follow-up and
an additional 3 during long-term follow-up), of which none
were related to either the procedure or the device. The
causes of death were mainly due to the normal sequelae of
long-term hypertension: 3 intracerebral hemorrhages; 2
Figure 4 Proportion of Subjects That Achieved SBP <140 mm
Data are displayed for the 2 randomized groups. Red bars  BAT is off; green ba
Figure 5 Observed Mean Change in SBP
Data with standard error of the change from the pre-implant time point are display
Abbreviations as in Figure 4.cardiopulmonary arrests; 1 ruptured abdominal aortic aneu-
rysm; and 1 drug overdose.
Primary safety endpoints. The results of the coprimary
endpoints are summarized in Table 2, and the most com-
mon adverse events that occurred for each endpoint during
the trial are shown in Table 3.
AT is on. BAT  baroreflex activation therapy; SBP  systolic blood pressure.
the 2 randomized groups. Red bars  BAT is off; green bars  BAT is on.Hg
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ree rate of 74.8% with a 95% 1-sided lower confidence
nterval bound of 70.5%, which is less than the pre-specified
bjective performance criterion of 82% (p  1.00). The
ajority of these events are related to the carotid sinus lead
lacement and involved transient (4.4%) or permanent nerve
njury (4.8% with some residual effect) that occurred at the
ime of implant. Additionally, there were 4.8% of subjects
ith a general surgical complication and 2.6% with either a
espiratory complaint or a wound complication following
mplant. All other events occurred at a rate of less than 2%.
he majority (76%) of procedure-related adverse events
esolved completely. There were no procedure-related
eaths.
BAT SAFETY. BAT safety yielded a therapy-related event-
free rate in Group A of 91.7% and in Group B of 89.3%
(p  0.001). The only event occurring at a rate of greater
han 2% in either group was for hypertensive emergency,
ith 40% reduction in rate of hypertensive events in
roup A.
DEVICE SAFETY. Device safety yielded an event-free rate of
87.2% with a 95% 1-sided lower confidence interval bound
of 83.8%, which exceeded the pre-specified objective per-
formance criterion of 72% (p  0.001). The only event
occurring at a rate of greater than 2% was for hypertension-
related stroke at 2.3%.
Discussion
The Rheos Pivotal Trial was the first large-scale, double-
blind, randomized, placebo-controlled device trial in pa-
tients with resistant HTN. The trial did not meet 2 of the
5 pre-specified coprimary endpoints in the short-term safety
and the short-term efficacy analyses. In addition, the pre-
specified coprimary endpoint for sustained efficacy as de-
signed may not provide the best evidence for the long-term
efficacy of BAT. However, as compared with pre-implant
values, mean reductions in SBP of up to 35 mm Hg were
observed at the Month 12 time point in all subjects
Summary of Adverse EventsTable 3 Summary of Adverse Events
Procedural 68 (25.5)
Surgical complication 13 (4.8)
Nerve injury with residual
deficit
13 (4.8)
Transient nerve injury 12 (4.4)
Respiratory complication 7 (2.6)
Wound complication 7 (2.6)
BAT
Hypertensive crisis (Group A) 9 (5.0)
Hypertensive crisis (Group B) 7 (8.3)
Device 34 (12.8)
Hypertension-related stroke 6 (2.3)
Values are n (%).
BAT  baroreflex activation therapy.participating in the trial. Additionally, over 50% of subjectswere able to achieve a SBP of 140 mm Hg with BAT.
The observation that during the initial 6 months of the trial,
the subjects receiving BAT experienced a 40% reduction in
rate of serious adverse events for hypertensive urgency
highlights an important aspect to the potential utility profile
of BAT.
The SBP reductions observed with BAT in this trial are
comparable to the results of the DEBuT (Device Based
Therapy) feasibility study in which SBP was reduced from
180 mm Hg by 30 mm Hg after 12 months of BAT in 26
subjects (9). In addition, it is important to note that the
reductions observed within this study following 6 months of
treatment with BAT are comparable across the 2 random-
ized groups and the 45 subjects from the open-label arm
(10), with reductions of 26, 33, and 33 mm Hg from
pre-implant for Group A, Group B, and open-label, respec-
tively. This magnitude of SBP reduction has the potential to
significantly reduce the impact of cardiovascular disease. A
recent meta-analysis concluded that a 30 mm Hg drop in
SBP among hypertensive patients results in 60% to 75%
reduction in the incidence of stroke and a 50% to 60%
reduction in the incidence of myocardial infarction and
sudden cardiac death (11). Likewise, the proportion of
patients achieving SBP 140 mm Hg was 42%, 51%, and
53% in Group A, Group B, and open-label (10), respec-
tively, after 6 months of BAT. Considering the average
pre-implant SBP of this cohort and the intensive medical
therapy applied throughout the trial, the rate of reaching
SBP 140 mm Hg is noteworthy and of greater clinical
significance than an arbitrarily defined reduction in SBP.
The results of 2 other trials of similar patient populations
with resistant HTN have recently been published, providing
some perspective for BAT-related SBP reduction (12,13).
Six months following renal denervation, 46 patients showed
a reduction of 32  23 mm Hg (baseline SBP: 178 mm Hg
on 5.2 medications) with 39% reaching a SBP 140 mm
Hg (12). After 14 weeks of treatment with an endothelin
type A–selective receptor antagonist, 364 patients showed a
reduction of 15  14 mm Hg (baseline SBP: 151 mm Hg
with 36% of patients on 4 medications) with 48% reach-
ing goal SBP (13).
Although the implant procedure safety did not meet the
pre-specified 82% event-free objective performance crite-
rion based on historic implant safety of implantable
cardioverter-defibrillators, the adverse event profile com-
pares favorably with results from endarterectomy trials,
which are more like the dissection for the Rheos procedure
in the carotid region. For example, the North American
Symptomatic Carotid Endarterectomy trial reported 8.6%
cranial nerve injury and 9.3% wound complications for
unilateral procedures (14). A recent literature review reports
rates of cranial nerve injuries in 10 carotid endarterectomy
trials published since 2000 to be in the range of 2.2% to 59%
(15). It is not surprising that nerve injury was the main
contributor to the event rate as the carotid sinus region is
richly innervated. Residual effects were generally modest,
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is interesting to note that, when optimized, the majority of
subjects (75%) were programmed to a unilateral pathway.
This suggests that the complexity and duration of the
implant procedure could be reduced by performing unilat-
eral implants, thereby reducing the likelihood of nerve
injury and other procedure-related safety issues.
The experimental design required assumptions that could
not be verified a priori due to the novelty of the device and
the patient population being studied. For example, the trial
assumed a standard deviation of 15 mm Hg in the reduction
of SBP from Month 0 to Month 6, whereas the observed
standard deviation of the difference exceeded 27 mm Hg. In
addition, the reduction in SBP in Group B was larger than
anticipated during the first 6 months of the trial. The high
variability and reduction in Group B could be explained by
several factors. Although the BpTRU device was used with
an averaging technique shown to correlate with ambulatory
BP (8), BP readings were taken 4 to 6 h post-medication
rather than at trough, and the protocol contained no
restrictions on dosing of or changes to antihypertensive
medication. In addition, the trial design did not have a
run-in period during screening to allow for several qualify-
ing BP measurements to be made on separate days, which
might have helped to reduce variability and lessen the
false-positive rate. Finally, the dichotomized responder anal-
ysis in which SBP was measured only once at 2 instances of
time was particularly vulnerable to excess variability with the
change measured from Month 0 (1 month post-implant), a
point at which each subject was at a different stage of recovery.
Because the design could not take into account the full range of
confounding factors associated with excess variability, Haw-
thorne effect, and placebo effect, further clarification of these
issues is not possible.
Perspectives. BAT was evaluated in a large, diverse, het-
erogeneous sample of patients with resistant HTN. Clini-
cally significant and sustained SBP reductions were ob-
served, and the BAT and device adverse event–free rates
exceeded pre-specified objective performance criteria,
thereby providing additional evidence for safety and efficacy
of BAT. BAT reduced SBP despite intensive ongoing
medical therapy. At enrollment, subjects were taking more
than 5 medications on average. The spectrum of medical
therapies included the full range of standard-of-care drugs
with an emphasis on calcium channel blockers, renin-
angiotensin system inhibitors, and diuretic therapy. Ninety-
one percent of subjects were on beta-blockers and/or sym-
patholytic agents. Device programming was titratable and
programmable by time of day, which is particularly advan-
tageous in the context of offering a chronotherapeutic
approach to hypertension management. Ultimately, BAT
allowed a large percentage of difficult-to-treat patients to
achieve SBP 140 mm Hg. Shortcomings of the trial
design precluded 2 of the 5 pre-specified primary endpoints
from attaining statistical significance.Future clinical trials will address the limitations of this
study and further define the therapeutic benefit of BAT.
New technology for delivering BAT that involves a less
invasive implant procedure has been developed by CVRx
and is currently undergoing confirmatory study in Europe.
Acknowledgments
The authors wish to acknowledge the efforts of the patients,
the investigators, and the clinical research coordinators
involved in this trial at the following centers: Iowa Heart
Center (n  36); Florida Hospital/Cardiovascular Institute
(n  15); Academisch Ziekenhuis Maastricht (n  14);
USC University Hospital (n  14); Scott and White
Memorial Hospital (n  14); Medical School Hannover
(n 13); University of Rochester (n 13); Nebraska Heart
nstitute (n  12); Henry Ford Hospital (n  12); Baptist
ospital of East Tennessee (n  12); Allegheny General
ospital (n  11); Temple University Hospital (n  10);
lorida Cardiovascular Institute (n  10); the Ohio State
niversity Medical Center (n  9); Jobst Vascular Center
n  9); Washington University School of Medicine (n  8);
niversity of Kentucky (n  8); University of Alabama at
irmingham (n  8); Liberty Hospital (n  8); the GW
edical Faculty Associates (n  7); Swedish Medical
enter (n 7); Novant Clinical Research Institute (n 7);
he Methodist Hospital (n  6); University Hospitals Case
edical Center (n  6); the Lindner Center for Research
nd Education at the Christ Hospital (n  5); Sanford
esearch/USD (n  5); Oklahoma Cardiovascular Re-
earch Group (n 5); Rex Healthcare (n 4); Hackensack
niversity Medical Center (n  4); Jacksonville Center for
linical Research (n  4); Vascular and Interventional
pecialists of Orange County, Inc. (n  4); Heart and
ascular Institute of Florida South (n  4); Lancaster
eneral Hospital (n  3); SERRG, Inc. (n  3); Veteran
ffairs Medical Center (n  2); Columbia University
edical Center (n  2); University of Chicago (n  2); the
are Group (n  2); Virginia Commonwealth University
n  1); Saint Thomas Research Institute (n  1); Apex
ardiology Consultants (n  1); and the University of
innesota (n  1).
Reprint requests and correspondence: Dr. John D. Bisognano,
Cardiology Division, University of Rochester Medical Center, 601
Elmwood Avenue, Box 679-7, Rochester, New York 14642-8679.
E-mail: John_Bisognano@URMC.Rochester.edu.
REFERENCES
1. Calhoun DA, Jones D, Textor S, et al., American Heart Association
Professional Education Committee. Resistant hypertension: diagnosis,
evaluation, and treatment: a scientific statement from the American
Heart Association Professional Education Committee of the Council
for High Blood Pressure Research. Circulation 2008;117:e510–26.
2. Acelajado MC, Calhoun DA. Resistant hypertension, secondary
hypertension, and hypertensive crises: diagnostic evaluation and treat-
ment. Cardiol Clin 2010;28:639–54.
3. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of
evaluation and treatment. J Am Coll Cardiol 2008;52:1749–57.
773JACC Vol. 58, No. 7, 2011 Bisognano et al.
August 9, 2011:765–73 Baroreflex Activation Therapy in Hypertension4. Grassi G. Sympathetic neural activity in hypertension and related
diseases. Am J Hypertens 2010;23:1052–60.
5. Heusser K, Tank J, Engeli S, et al. Carotid baroreceptor stimulation,
sympathetic activity, baroreflex function, and blood pressure in hyper-
tensive patients. Hypertension 2010;55:619–26.
6. Wustmann K, Kucera JP, Scheffers I, et al. Effects of chronic
baroreceptor stimulation on the autonomic cardiovascular regulation in
patients with drug-resistant arterial hypertension. Hypertension 2009;
54:530–6.
7. Illig KA, Levy M, Sanchez L, et al. An implantable carotid sinus
stimulator for drug-resistant hypertension: surgical technique and
short-term outcome from the multicenter phase II Rheos feasibility
trial. J Vasc Surg 2006;44:1213–8.
8. Beckett L, Godwin M. The BpTRU automatic blood pressure
monitor compared to 24 hour ambulatory blood pressure monitoring
in the assessment of blood pressure in patients with hypertension.
BMC Cardiovasc Disord 2005;5:18.
9. Scheffers IJM, Kroon AA, Schmidli J, et al. Novel baroreflex activation
therapy in resistant hypertension: results of a European multi-center
feasibility study. J Am Coll Cardiol 2010;56:1254–8.10. Bakris G, Bisgnano J, Nadim M, et al. Achievement of blood pressure
goal in patients with resistant hypertension treated with Baroreflex
Activation Therapy. J Hypertens 2010;26 E-Suppl A:282.
11. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs
in the prevention of cardiovascular disease: meta-analysis of 147
randomised trials in the context of expectations from prospective
epidemiological studies. BMJ 2009;338:b1665.
12. Symplicity HTN-2 Investigators. Renal sympathetic denervation in
patients with treatment-resistant hypertension (the Symplicity
HTN-2 trial): a randomized controlled trial. Lancet 2010;376:1903–9.
13. Bakris G, Lindholm L, Black H, et al. Divergent results using clinic
and ambulatory blood pressures: report of a darusentan-resistant
hypertension trial. Hypertension 2010;56:824–30.
14. Ferguson GG, Eliasziw M, Barr HW, et al. The North American
Symptomatic Carotid Endarterectomy Trial: surgical results in 1415
patients. Stroke 1999;30:1751–8.
15. Sajid MS, Vijaynagar B, Singh P, Hamilton G. Literature review of
cranial nerve injuries during carotid endarterectomy. Acta Chir Belg
2007;107:25–8.Key Words: baroreflex y medical device y resistant hypertension.
